Literature DB >> 7649969

Anxiety symptom relief in depression treatment outcomes.

M B Keller1, D L Hanks.   

Abstract

Depressive and anxiety disorders have a high lifetime prevalence--8% and 15%, respectively. Unipolar depression has a 5% lifetime prevalence, whereas the prevalence rate for all depressive disorders is between 6% to 8% at a minimum. Each disorder has also been found to have a high rate of chronicity and recurrence. It has become increasingly apparent over the past decade that within episodes of depression, anxiety symptoms often exist. Whether this phenomenon indicates two separate but comorbid illnesses or that the presence of anxiety symptoms is part of the course of depression is of particular significance for diagnosis and treatment. The author focuses on the issues of differential diagnosis, including physical and emotional manifestations of the illness. The consequences of comorbid anxiety and depression can be serious, ranging from social and physical disability to suicidal ideation and behavior. Anxiety has been found to be a predictor of suicide in depressed patients, and since anxiety symptoms respond to intervention, they can also serve as an indication of type of treatment. Antidepressants should be used in treating anxiety or panic symptoms when depression is also present. In studies comparing benzodiazepines, monoamine oxidase inhibitors (MAOIs), serotonin selective reuptake inhibitors (SSRIs), and tricyclic antidepressants (TCAs) in the treatment of concurrent anxiety and depression, all have some measure of success depending on the degree of depression and the type of anxiety disorder. SSRIs may have the least amount of side effects, but more long-term studies are needed to determine the long-term efficacy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7649969

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

1.  Mixed Anxiety and Depression : Diagnosis and Treatment Options.

Authors:  D Bakish; R Habib; C L Hooper
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

2.  Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after successful acute treatment of mild to moderate depression--rationale and study design.

Authors:  S Kasper; A Dienel; M Kieser
Journal:  Int J Methods Psychiatr Res       Date:  2004       Impact factor: 4.035

3.  Anxiety and Depression: Optimizing Treatments.

Authors:  James C. Ballenger
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-06

4.  Psychiatric and Somatic Markers of Anxiety: Identification and Pharmacologic Treatment.

Authors:  Alan J. Gelenberg
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-04

5.  Escitalopram: A New SSRI for the Treatment of Depression in Primary Care.

Authors:  Larry Culpepper
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2002-12

6.  Family Members' Perspectives of Health Care System Interactions With Suicidal Patients and Responses to Suicides: Protocol for a Qualitative Research Study.

Authors:  Erin Bryksa; Reham Shalaby; Laura Friesen; Kirsten Klingle; Graham Gaine; Liana Urichuk; Shireen Surood; Vincent Agyapong
Journal:  JMIR Res Protoc       Date:  2019-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.